Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol. 2008;102 (Suppl):1K-34K.
 Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Diab Vasc Dis Res. 2008; 5:319-35.
 Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-78
 Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-393
 Alsheikh-Ali AA, Lin JL, Abourjaily P, Ahearn D, Kuvin JT, Karas RH. Prevalence of low highdensity lipoprotein cholesterol in patients with documented coronary heart disease or riskequivalent and controlled low-density lipoprotein cholesterol. Am J Cardiol. 2007;100:1499-1501
 Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS.
Association of the metabolic syndrome with history of myocardial infarction
and stroke in the Thi
|SOURCE Residual Risk Reduction Initiative Foundation|
Copyright©2009 PR Newswire.
All rights reserved